Phase 3 trials are ongoing and no version is approved for prescription use in the UK
Tesamorelins enhanced stability allows for less frequent dosing in research protocols, while Ipamorelins longer half-life compared to Sermorelin provides sustained activity despite its smaller molecular size
Regular follow-up visits also provide opportunities to celebrate progress beyond the scale, including improved energy levels, healthier blood pressure, better blood sugar control, and increased confidence
consider reducing doses of these medications when initiating tirzepatide Signs of acute kidney injury, particularly in patients experiencing severe gastrointestinal adverse effects with dehydration Symptoms of pancreatitis (severe abdominal pain radiating to the back, nausea, vomiting) Gallbladder disease (right upper quadrant pain, fever, jaundice) Gastrointestinal adverse effects, which occur commonly but are usually self-limited Tirzepatide is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis
C.et al (2020)
PMID 23352028